1. Home
  2. KALV vs BH Comparison

KALV vs BH Comparison

Compare KALV & BH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.72

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Biglari Holdings Inc. Class B

BH

Biglari Holdings Inc. Class B

HOLD

Current Price

$305.58

Market Cap

971.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
BH
Founded
N/A
1934
Country
United States
United States
Employees
N/A
2359
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
971.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KALV
BH
Price
$26.72
$305.58
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.60
N/A
AVG Volume (30 Days)
4.1M
59.5K
Earning Date
07-09-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
$185.42
N/A
Revenue Next Year
$59.23
N/A
P/E Ratio
N/A
$597.67
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$230.12
52 Week High
$26.85
$483.60

Technical Indicators

Market Signals
Indicator
KALV
BH
Relative Strength Index (RSI) 75.25 47.87
Support Level $14.66 $299.54
Resistance Level N/A $321.70
Average True Range (ATR) 0.57 13.06
MACD 0.45 0.75
Stochastic Oscillator 98.41 74.42

Price Performance

Historical Comparison
KALV
BH

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About BH Biglari Holdings Inc. Class B

Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.

Share on Social Networks: